Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication
Tóm tắt
Từ khóa
Tài liệu tham khảo
Catlett-Falcone, 1999, Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells, Immunity, 10, 105, 10.1016/S1074-7613(00)80011-4
Grandis, 1998, Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitro, J Clin Invest., 102, 1385, 10.1172/JCI3785
Lou, 2000, Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway, Prostate, 42, 239, 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G
Zhang, 2002, Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis, Oncogene, 21, 217, 10.1038/sj.onc.1205004
Kaido, 2004, Interleukin-6 augments hepatocyte growth factor-induced liver regeneration; involvement of STAT3 activation, Hepatogastroenterology, 51, 1667
Hung, 2001, Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells, J Biol Chem., 276, 12395, 10.1074/jbc.M010715200
Garcia, 2001, Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells, Oncogene, 20, 2499, 10.1038/sj.onc.1204349
Lin, 2000, STAT signaling in the pathogenesis and treatment of leukemias, Oncogene, 19, 2496, 10.1038/sj.onc.1203486
Schwaller, 2000, Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2, Mol Cell, 6, 693, 10.1016/S1097-2765(00)00067-8
Bromberg, 1996, Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma, Proc Natl Acad Sci USA., 93, 7673, 10.1073/pnas.93.15.7673
Shankaran, 2001, IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, 410, 1107, 10.1038/35074122
Gao, 2007, Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas, J Clin Invest., 117, 3846, 10.1172/JCI31871
Ernst, 2008, STAT3 and STAT1 mediate IL-11–dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice, J Clin Invest., 118, 1727, 10.1172/JCI34944
Arredondo, 2006, Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of α7 nicotinic receptor in oral keratinocytes, FASEB J., 20, 2093, 10.1096/fj.06-6191com
Sano, 2005, Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation, Cancer Res., 65, 5720, 10.1158/0008-5472.CAN-04-4359
O'shea, 2012, JAK and STAT signaling molecules in immunoregulation and immune-mediated disease, Immunity, 36, 542, 10.1016/j.immuni.2012.03.014
Rauch, 2013, The regulation of inflammation by interferons and their STATs, JAKSTAT, 2, e23820, 10.4161/jkst.23820
Rani, 2016, STAT5 in cancer and immunity, J Interferon Cytokine Res., 36, 226, 10.1089/jir.2015.0054
Glosson, 2012, Wheezing and itching: the requirement for STAT proteins in allergic inflammation, JAKSTAT, 1, 3, 10.4161/jkst.19086
O'shea, 2011, Genomic views of STAT function in CD4+ T helper cell differentiation, Nat Rev Immunol., 11, 239, 10.1038/nri2958
Stritesky, 2011, Changing the STATus quo in T helper cells, Transcription, 2, 179, 10.4161/trns.2.4.16614
Aggarwal, 2006, Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution, Ann N Y Acad Sci., 1091, 151, 10.1196/annals.1378.063
Chai, 2016, Targeting transcription factor STAT3 for cancer prevention and therapy, Pharmacol Ther., 162, 86, 10.1016/j.pharmthera.2015.10.004
Subramaniam, 2014, Possible involvement of signal transducer and activator of transcription-3 (STAT3) signaling pathway in the initiation and progression of hepatocellular carcinoma, Perspectives in Cancer Prevention-Translational Cancer Research, 73, 10.1007/978-81-322-1533-2_6
Wong, 2017, Do STAT3 inhibitors have potential in the future for cancer therapy?, Expert Opin Investig Drugs, 26, 883, 10.1080/13543784.2017.1351941
Wingelhofer, 2018, Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer, Leukemia, 32, 1713, 10.1038/s41375-018-0117-x
Able, 2017, STAT5-interacting proteins: a synopsis of proteins that regulate STAT5 activity, Biology (Basel), 6, 20, 10.3390/biology6010020
Hennighausen, 2008, Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B, Genes Dev., 22, 711, 10.1101/gad.1643908
Ihle, 2001, The Stat family in cytokine signaling, Curr Opin Cell Biol., 13, 211, 10.1016/S0955-0674(00)00199-X
Lee, 2017, Capsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer, Oncotarget, 8, 17700, 10.18632/oncotarget.10775
Zhang, 2016, Nimbolide-induced oxidative stress abrogates STAT3 signaling cascade and inhibits tumor growth in transgenic adenocarcinoma of mouse prostate model, Antioxid Redox Signal., 24, 575, 10.1089/ars.2015.6418
Kim, 2018, Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model, Cancer Lett., 431, 123, 10.1016/j.canlet.2018.05.038
Lee, 2015, Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel, Oncotarget, 6, 6386, 10.18632/oncotarget.3443
Rajendran, 2012, Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo, Cancer Prev Res., 5, 631, 10.1158/1940-6207.CAPR-11-0420
Leonard, 1998, Jaks and STATs: biological implications, Annu Rev Immunol., 16, 293, 10.1146/annurev.immunol.16.1.293
Xue, 2002, Serine phosphorylation of Stat5 proteins in lymphocytes stimulated with IL-2, Int Immunol., 14, 1263, 10.1093/intimm/dxf101
Scheel, 2011, Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast, Cell, 145, 926, 10.1016/j.cell.2011.04.029
Zhang, 2017, Cardamonin represses proliferation, invasion, and causes apoptosis through the modulation of signal transducer and activator of transcription 3 pathway in prostate cancer, Apoptosis, 22, 158, 10.1007/s10495-016-1313-7
Liu, 2010, IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells, Cell Cycle, 9, 3423, 10.4161/cc.9.17.12946
Mohan, 2014, Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo, J Biol Chem., 289, 34296, 10.1074/jbc.M114.601104
Baek, 2016, Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: role in apoptosis induction and radiosensitization in head and neck tumor cells, Phytomedicine, 23, 566, 10.1016/j.phymed.2016.02.011
Subramaniam, 2013, Potential role of signal transducer and activator of transcription (STAT) 3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma, Biochim Biophys Acta, 1835, 46, 10.1016/j.bbcan.2012.10.002
Kim, 2014, β-caryophyllene oxide inhibits constitutive and inducible STAT3 signaling pathway through induction of the SHP-1 protein tyrosine phosphatase, Mol Carcinog., 53, 793, 10.1002/mc.22035
Leaman, 1996, Regulation of STAT-dependent pathways by growth factors and cytokines, FASEB J., 10, 1578, 10.1096/fasebj.10.14.9002549
Hirano, 2000, Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors, Oncogene, 19, 2548, 10.1038/sj.onc.1203551
Kim, 2015, 6-Shogaol exerts anti-proliferative and pro-apoptotic effects through the modulation of STAT3 and MAPKs signaling pathways, Mol Carcinog., 54, 1132, 10.1002/mc.22184
Baek, 2017, Ginkgolic acid C 17: 1, derived from Ginkgo biloba leaves, suppresses constitutive and inducible STAT3 activation through induction of PTEN and SHP-1 tyrosine phosphatase, Molecules, 22, 276, 10.3390/molecules22020276
Haura, 2005, Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer, Nat Rev Clin Oncol., 2, 315, 10.1038/ncponc0195
Shanmugam, 2015, Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model, Mol Carcinog., 54, 971, 10.1002/mc.22166
Ma, 2006, Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements, Cell Signal., 18, 1117, 10.1016/j.cellsig.2005.06.016
Sethi, 2014, Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo, Mol Cancer, 13, 66, 10.1186/1476-4598-13-66
Jing, 2005, Targeting Stat3 in cancer therapy, Anticancer Drugs, 16, 601, 10.1097/00001813-200507000-00002
Lee, 2014, Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases, Cancer Lett., 345, 140, 10.1016/j.canlet.2013.12.008
Siveen, 2014, Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors, Biochim Biophys Acta, 1845, 136, 10.1016/j.bbcan.2013.12.005
Li, 2010, Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells, Cancer Lett., 292, 197, 10.1016/j.canlet.2009.12.003
Kannaiyan, 2011, Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells, Br J Pharmacol., 164, 1506, 10.1111/j.1476-5381.2011.01449.x
Kazansky, 1999, Differential effects of prolactin andsrc/abl kinases on the nuclear translocation of STAT5B and STAT5A, J Biol Chem., 274, 22484, 10.1074/jbc.274.32.22484
Rajendran, 2011, γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent, Br J Pharmacol., 163, 283, 10.1111/j.1476-5381.2010.01187.x
Turkson, 2000, STAT proteins: novel molecular targets for cancer drug discovery, Oncogene, 19, 6613, 10.1038/sj.onc.1204086
Li, 2013, Garcinol, a polyisoprenylated benzophenone modulates multiple pro-inflammatory signaling cascades leading to suppression of growth and survival of head and neck carcinoma, Cancer Prev Res., 6, 843, 10.1158/1940-6207.CAPR-13-0070
Silva, 2004, Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis, Oncogene, 23, 8017, 10.1038/sj.onc.1208159
Yamashita, 1998, Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells, J Biol Chem., 273, 30218, 10.1074/jbc.273.46.30218
Wang, 2003, Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands, J Cell Biol., 161, 583, 10.1083/jcb.200212066
Park, 2001, Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: impact on STAT5 transcriptional activity, Mol Endocrinol., 15, 2157, 10.1210/mend.15.12.0746
Shanmugam, 2011, Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice, J Mol Med., 89, 713, 10.1007/s00109-011-0746-2
Rajendran, 2011, Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo, Clin Cancer Res., 17, 1425, 10.1158/1078-0432.CCR-10-1123
Xiong, 2009, Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells, Lab Invest., 89, 717, 10.1038/labinvest.2009.11
Coffer, 2000, The role of STATs in myeloid differentiation and leukemia, Oncogene, 19, 2511, 10.1038/sj.onc.1203479
Ito, 2004, Oncogenic potential of the RUNX gene family: ‘overview’, Oncogene, 23, 4198, 10.1038/sj.onc.1207755
Cameron, 2004, The RUNX genes: lineage-specific oncogenes and tumor suppressors, Oncogene, 23, 4308, 10.1038/sj.onc.1207130
Osato, 2004, Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia, Oncogene, 23, 4284, 10.1038/sj.onc.1207779
Pratap, 2011, Metastatic bone disease: role of transcription factors and future targets, Bone, 48, 30, 10.1016/j.bone.2010.05.035
Thomas, 2004, Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma, J Cell Biol., 167, 925, 10.1083/jcb.200409187
Ito, 2005, RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization, Cancer Res., 65, 7743, 10.1158/0008-5472.CAN-05-0743
Ulloa, 1999, Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway, Nature, 397, 710, 10.1038/17826
Li, 2002, Causal relationship between the loss of RUNX3 expression and gastric cancer, Cell, 109, 113, 10.1016/S0092-8674(02)00690-6
Yano, 2006, The RUNX3 tumor suppressor upregulates bim in gastric epithelial cells undergoing transforming growth factorβ-induced apoptosis, Mol Cell Biol., 26, 4474, 10.1128/MCB.01926-05
Zheng, 2018, DNA methylation affects metastasis of renal cancer and is associated with TGF-β/RUNX3 inhibition, Cancer Cell Int., 18, 56, 10.1186/s12935-018-0554-7
Nakashima, 1999, Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300, Science, 284, 479, 10.1126/science.284.5413.479
Kim, 2003, Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation, Genes Dev., 17, 1979, 10.1101/gad.1119303
Miyazono, 2004, Coordinate regulation of cell growth and differentiation by TGF-β superfamily and RUNX proteins, Oncogene, 23, 4232, 10.1038/sj.onc.1207131
Niu, 2005, Role of Stat3 in regulating p53 expression and function, Mol Cell Biol., 25, 7432, 10.1128/MCB.25.17.7432-7440.2005
Chin, 1996, Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1, Science, 272, 719, 10.1126/science.272.5262.719
Macleod, 1995, p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage, Genes Dev., 9, 935, 10.1101/gad.9.8.935
Townsend, 2004, STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis, J Biol Chem., 279, 5811, 10.1074/jbc.M302637200
Kaplan, 1998, Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice, Proc Natl Acad Sci USA., 95, 7556, 10.1073/pnas.95.13.7556
Baran-Marszak, 2004, Differential roles of STAT1α and STAT1β in fludarabine-induced cell cycle arrest and apoptosis in human B cells, Blood, 104, 2475, 10.1182/blood-2003-10-3508
Youlyouz-Marfak, 2008, Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents, Cell Death Differ., 15, 376, 10.1038/sj.cdd.4402270
Gamero, 2018, p53 inactivation and STAT2 cooperate to enhance migration and metastasis of colon tumor cells, AACR, 10.1158/1538-7445.AM2018-3157
Karin, 2005, NF-κB: linking inflammation and immunity to cancer development and progression, Nat Rev Immunol., 5, 749, 10.1038/nri1703
Baud, 2009, Is NF-κB a good target for cancer therapy?, Nature Rev Drug Discov., 8, 33, 10.1038/nrd2781
Bollrath, 2009, gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis, Cancer Cell, 15, 91, 10.1016/j.ccr.2009.01.002
Grivennikov, 2009, IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer, Cancer Cell, 15, 103, 10.1016/j.ccr.2009.01.001
Lee, 2009, Persistently activated Stat3 maintains constitutive NF-κB activity in tumors, Cancer Cell, 15, 283, 10.1016/j.ccr.2009.02.015
Yang, 2007, Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB, Genes Dev., 21, 1396, 10.1101/gad.1553707
Yu, 2007, Tumour immunology: crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment, Nat Rev Immunol., 7, 41, 10.1038/nri1995
Basseres, 2006, Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression, Oncogene, 25, 6817, 10.1038/sj.onc.1209942
Zhong, 1994, Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6, Science, 264, 95, 10.1126/science.8140422
Yu, 2004, The STATs of cancer—new molecular targets come of age, Nat Rev Cancer, 4, 97, 10.1038/nrc1275
Ogura, 2008, Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction, Immunity, 29, 628, 10.1016/j.immuni.2008.07.018
Pandurangan, 2014, Signal transducer and activator of transcription 3-a promising target in colitis-associated cancer, Asian Pac J Cancer Prev., 15, 551, 10.7314/apjcp.2014.15.2.551
Murone, 2016, Debio 0617B inhibits growth of STAT3-driven solid tumors through combined inhibition of JAK, SRC, and class III/V receptor tyrosine kinases, Mol Cancer Ther., 15, 2334, 10.1158/1535-7163.MCT-15-0974
Wu, 2015, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol Sci., 36, 422, 10.1016/j.tips.2015.04.005
Pei, 2018, Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis, Sci Rep., 8, 5273, 10.1038/s41598-018-23569-y
Ghoreschi, 2009, Janus kinases in immune cell signaling, Immunol Rev., 228, 273, 10.1111/j.1600-065X.2008.00754.x
Gehringer, 2014, Novel Hinge-binding motifs for janus kinase 3 inhibitors: a comprehensive structure–activity relationship study on tofacitinib bioisosteres, ChemMedChem, 9, 2516, 10.1002/cmdc.201402252
Winthrop, 2017, The emerging safety profile of JAK inhibitors in rheumatic disease, Nat Rev Rheumatol., 13, 234, 10.1038/nrrheum.2017.23
Lavecchia, 2011, STAT-3 inhibitors: state of the art and new horizons for cancer treatment, Curr Med Chem., 18, 2359, 10.2174/092986711795843218
Buettner, 2002, Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention, Clin Cancer Res., 8, 945
Wingelhofer, 2018, Pharmacologic inhibition of STAT5 in acute myeloid leukemia, Leukemia, 32, 1135, 10.1038/s41375-017-0005-9
Nelson, 2011, The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors, Blood, 117, 3421, 10.1182/blood-2009-11-255232
Arora, 2018, The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies, Cancers (Basel), 10, 327, 10.3390/cancers10090327
Shin, 2009, Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells, Cancer Res., 69, 193, 10.1158/0008-5472.CAN-08-2575
Bhutani, 2007, Capsaicin is a novel blocker of constitutive and interleukin-6–inducible STAT3 activation, Clin Cancer Res., 13, 3024, 10.1158/1078-0432.CCR-06-2575
Bharti, 2003, Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells, J Immunol., 171, 3863, 10.4049/jimmunol.171.7.3863
Oi, 2016, STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma, Int J Oncol., 49, 2275, 10.3892/ijo.2016.3757
Amit-Vazina, 2005, Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells, Br J Cancer, 93, 70, 10.1038/sj.bjc.6602637
Pinz, 2014, The natural chemopreventive agent sulforaphane inhibits STAT5 activity, PLoS ONE, 9, e99391, 10.1371/journal.pone.0099391
Alshamsan, 2010, The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine, Biomaterials, 31, 1420, 10.1016/j.biomaterials.2009.11.003
Turkson, 2004, STAT proteins as novel targets for cancer drug discovery, Expert Opin Ther Targets, 8, 409, 10.1517/14728222.8.5.409
Anastasov, 2009, Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer, J Hematopathol., 2, 9, 10.1007/s12308-008-0020-x
Peer, 2011, Special delivery: targeted therapy with small RNAs, Gene Ther., 18, 1127, 10.1038/gt.2011.56
Weinstein, 2016, Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies, Proc Natl Acad Sci USA., 113, E16, 10.1073/pnas.1519273113
de Fougerolles, 2007, Interfering with disease: a progress report on siRNA-based therapeutics, Nat Rev Drug Discov., 6, 443, 10.1038/nrd2310
Paddison, 2002, Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells, Genes Dev., 16, 948, 10.1101/gad.981002
Konnikova, 2003, Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells, BMC Cancer, 3, 23, 10.1186/1471-2407-3-23
Konnikova, 2005, Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells, Cancer Res., 65, 6516, 10.1158/0008-5472.CAN-05-0924
Cao, 2011, STAT5 regulates glioma cell invasion by pathways dependent and independent of STAT5 DNA binding, Neurosci Lett., 487, 228, 10.1016/j.neulet.2010.10.028
Gu, 2010, Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo, Endocr Relat Cancer, 17, 481, 10.1677/ERC-09-0328
Choi, 2011, Granulocyte macrophage-colony stimulating factor shows anti-apoptotic activity in neural progenitor cells via JAK/STAT5-Bcl-2 pathway, Apoptosis, 16, 127, 10.1007/s10495-010-0552-2
Gao, 2005, Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells, Acta Pharmacol Sin., 26, 377, 10.1111/j.1745-7254.2005.00053.x
Jin, 2010, The effect of STAT5 silenced by siRNA on proliferation, apoptosis and invasion of esophageal carcinoma cell line EC9706, Chinese German J Clin Oncol., 9, 692, 10.1007/s10330-010-0717-z
Kunigal, 2009, Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer, Int J Oncol., 34, 1209, 10.3892/ijo_00000249
Xiong, 2012, Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition, J Biol Chem., 287, 5819, 10.1074/jbc.M111.295964
Xu, 2013, The upregulation of signal transducer and activator of transcription 5-dependent microRNA-182 and microRNA-96 promotes ovarian cancer cell proliferation by targeting forkhead box O3 upon leptin stimulation, Int J Biochem Cell Biol., 45, 536, 10.1016/j.biocel.2012.12.010
Zhang, 2016, SENP1 regulates hepatocyte growth factor-induced migration and epithelial-mesenchymal transition of hepatocellular carcinoma, Tumour Biol., 37, 7741, 10.1007/s13277-015-4406-y
Tatiparti, 2017, siRNA delivery strategies: a comprehensive review of recent developments, Nanomaterials, 7, 77, 10.3390/nano7040077
Guven, 2005, Efficient gene transfer into primary human natural killer cells by retroviral transduction, Exp Hematol., 33, 1320, 10.1016/j.exphem.2005.07.006
Yang, 2009, Lentivirus-mediated shRNA interference targeting STAT3 inhibits human pancreatic cancer cell invasion, World J Gastroenterol., 15, 3757, 10.3748/wjg.15.3757
Emeagi, 2013, Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy, Gene Ther., 20, 1085, 10.1038/gt.2013.35
Wang, 2012, Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma, Cancer Gene Ther., 19, 822, 10.1038/cgt.2012.65
Cao, 2011, EGF stimulates cyclooxygenase-2 expression through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells, Int J Oncol., 39, 383, 10.3892/ijo.2011.1053
Zhang, 2007, Cationic lipids and polymers mediated vectors for delivery of siRNA, J Control Release, 123, 1, 10.1016/j.jconrel.2007.07.016
Zhao, 2015, Knockdown of STAT3 expression in SKOV3 cells by biodegradable siRNA–PLGA/CSO conjugate micelles, Colloids Surf B Biointerfaces, 127, 155, 10.1016/j.colsurfb.2015.01.034
Hou, 2013, Melittin derived peptides for nanoparticle based siRNA transfection, Biomaterials, 34, 3110, 10.1016/j.biomaterials.2013.01.037
Soenen, 2009, Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model, Biomaterials, 30, 3691, 10.1016/j.biomaterials.2009.03.040
Ballarín-González, 2012, Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions, Adv Drug Deliv Rev., 64, 1717, 10.1016/j.addr.2012.07.004
Forti, 2016, A bridge to silencing: Co-assembling anionic nanoparticles of siRNA and hyaluronan sulfate via calcium ion bridges, J Control Release, 232, 215, 10.1016/j.jconrel.2016.04.033
Lv, 2006, Toxicity of cationic lipids and cationic polymers in gene delivery, J Control Release, 114, 100, 10.1016/j.jconrel.2006.04.014
Alshamsan, 2008, Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine, Mol Pharma., 6, 121, 10.1021/mp8000815
Das, 2014, Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo, Toxicol Lett., 225, 454, 10.1016/j.toxlet.2014.01.009
Su, 2012, PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells, Int J Nanomed., 7, 4269, 10.2147/IJN.S33666
Yin, 2013, Functional graphene oxide as a plasmid-based Stat3 siRNA carrier inhibits mouse malignant melanoma growth in vivo, Nanotechnology, 24, 105102, 10.1088/0957-4484/24/10/105102
Yuan, 2011, Recent advances of siRNA delivery by nanoparticles, Expert Opin Drug Deliv., 8, 521, 10.1517/17425247.2011.559223
Heo, 2014, Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells, Biomaterials, 35, 590, 10.1016/j.biomaterials.2013.10.009
Molavi, 2010, Development of a poly (d, l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy, Mol Pharma., 7, 364, 10.1021/mp900145g
Labala, 2017, Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles, Int J Pharma., 525, 407, 10.1016/j.ijpharm.2017.03.087
Labala, 2016, Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma, Colloids Surf B Biointerfaces, 146, 188, 10.1016/j.colsurfb.2016.05.076
Tan, 2005, Surface modification of gold and quantum dot nanoparticles with chitosan for bioapplications, J Biomed Mater Res A, 75, 56, 10.1002/jbm.a.30410
Liang, 2011, Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo, Asian J Androl., 13, 481, 10.1038/aja.2010.167
Shi, 2018, Inorganic kernel-Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R, J Control Release, 279, 53, 10.1016/j.jconrel.2018.04.023
Luo, 2015, Nanovaccine loaded with poly I: C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo, Biomaterials, 38, 50, 10.1016/j.biomaterials.2014.10.050
Ou, 2018, Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy, J Control Release, 281, 84, 10.1016/j.jconrel.2018.05.018
Larmonier, 2008, Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL− tumors, J Immunol., 181, 6955, 10.4049/jimmunol.181.10.6955
Kim, 2012, Nanoparticle delivery of a peptide targeting EGFR signaling, J Control Release, 157, 279, 10.1016/j.jconrel.2011.08.014
Liu, 2013, Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway, Int Immunopharmacol., 17, 314, 10.1016/j.intimp.2013.06.020
Rathore, 2008, Simultaneous determination of hydrazinocurcumin and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation, J Pharma Biomed Anal., 46, 374, 10.1016/j.jpba.2007.09.019
Zhang, 2013, Hydrazinocurcumin encapsuled nanoparticles “re-educate” tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following STAT3 suppression, PLoS ONE, 8, e65896, 10.1371/journal.pone.0065896
Liao, 2011, Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity, Nanomedicine, 7, 665, 10.1016/j.nano.2011.03.001
Guorgui, 2018, Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice, Arch Biochem Biophys., 648, 12, 10.1016/j.abb.2018.04.012
Ma, 2015, STAT3 decoy oligodeoxynucleotides-loaded solid lipid nanoparticles induce cell death and inhibit invasion in ovarian cancer cells, PLoS ONE, 10, e0124924, 10.1371/journal.pone.0124924
Kotmakçi, 2017, Preparation and characterization of lipid nanoparticle/pDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells, Int J Pharma., 525, 101, 10.1016/j.ijpharm.2017.04.034
Xu, 2014, A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer, Eur J Surg Oncol., 40, 311, 10.1016/j.ejso.2013.11.012
Shahzad, 2011, Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles, Neoplasia, 13, 309, 10.1593/neo.101372
Ruvinov, 2015, Calcium–siRNA nanocomplexes: what reversibility is all about, J Control Release, 203, 150, 10.1016/j.jconrel.2015.02.029
Bondalapati, 2014, Rapid end-group modification of polysaccharides for biomaterial applications in regenerative medicine, Macromol Rapid Commun., 35, 1754, 10.1002/marc.201400354
Korin, 2017, GalNAc bio-functionalization of nanoparticles assembled by electrostatic interactions improves siRNA targeting to the liver, J Control Release, 266, 310, 10.1016/j.jconrel.2017.10.001
de Almeida, 2017, Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer, Int J Pharma., 525, 334, 10.1016/j.ijpharm.2017.03.086
Esposito, 2018, STAT3 gene silencing by aptamer-siRNA chimera as selective therapeutic for glioblastoma, Mol Ther Nucleic Acids, 10, 398, 10.1016/j.omtn.2017.12.021
Akhavan, 2013, De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients, Cancer Discov., 3, 534, 10.1158/2159-8290.CD-12-0502
Najar, 2013, EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line, Asian Pac J Cancer Prev., 14, 495, 10.7314/apjcp.2013.14.1.495
Jiang, 2016, Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles, Cancer Res., 76, 4470, 10.1158/0008-5472.CAN-15-2949
Théry, 2002, Exosomes: composition, biogenesis and function, Nat Rev Immunol., 2, 569, 10.1038/nri855